At ASGCT, the company will share data showing that its RNA achieves higher, more durable protein expression compared to other ...

Nucleic acid-based therapeutics, including antisense oligonucleotides (ASO), small interfering RNA (siRNA), messenger RNA (mRNA), immunomodulatory DNA/RNA, and gene-editing guide RNA (gRNA), hold ...

Targeted extended circulation LNP incorporating DARPins achieved complete B cell depletion in nonhuman primates through highly specific in vivo CD8+ T cell engineeringRobust study quantifies ...

While scientists have known for more than two decades that all cells use a strategy called RNA interference to regulate gene ...

Imagine a cancer treatment that precisely targets malignant cells, leaving healthy ones untouched. Consider, also, a cancer treatment that corrects abnormal protein synthesis to produce healthy ...

Financing led by Breyer Capital with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC, and other investors. Proceeds will advance APEXm p ...

The mRNA therapeutics industry faces a critical manufacturing challenge that threatens both product safety and commercial viability. Double-stranded RNA (dsRNA) formation during in vitro transcription ...

Financing led by Breyer Capital with participation from General Catalyst, Y Combinator, Metaplanet, SurgePoint Capital, ZAKA VC, and other investors Proceeds will advance APEXm™ platform and in vivo ...

What is an RNA vaccine? RNA vaccines, or messenger RNA (mRNA) vaccines, are a relatively new type of vaccine that delivers mRNA molecules to human cells, instructing them to produce specific antigens.

Phase 1 Data Shows a 43% Overall Response Rate at the Recommended Phase 2 Dose and Durable Responses Exceeding One Year and Ongoing, with a ...